      
<!-- modules/module48.html -->
<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Centrally acting agents - KMTC Pharmacology Notes</title>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Centrally acting agents - KMTC Pharmacology Notes</title>
    <meta name="description" content="This module covers Centrally acting antihypertensive agents like Methyldopa and Direct-Acting Vasodilators like Hydralazine hydrochloride.">
</head>
<body>
    <article class="learning-module" data-module="48">
        <nav class="module-nav">
            <div class="nav-links">
              <a href="../index.html">Home</a>
              <a href="module47.html">Previous</a>
              <a href="module49.html">Next</a>
            </div>
            <div class="module-progress">
              <span>Module 48 of 89</span>
            </div>
          </nav>

        <header class="module-header">
            <h1>Centrally acting agents</h1>
            <section class="module-objectives">
                <h2>üéØ Learning Objectives</h2>
                <ul>
                    <li>Describe centrally acting antihypertensive agents and their mechanisms of action.</li>
                    <li>Explain the uses, side effects, and nursing considerations for Methyldopa.</li>
                    <li>Detail the characteristics, uses, and contraindications of Hydralazine hydrochloride as a direct vasodilator.</li>
                    <li>Understand the nursing considerations for patients receiving centrally acting and direct-acting antihypertensive agents.</li>
                    <li>Compare and contrast centrally acting agents and direct vasodilators in managing hypertension.</li>
                </ul>
            </section>
        </header>

        <main class="module-content">
            <section class="content-section">
                <h2>üìö Centrally acting agents: Methyldopa</h2>
                <div class="content-block">
                    <p><strong>Centrally acting agents</strong> are antihypertensive drugs that work within the central nervous system (CNS) to lower blood pressure. Methyldopa is a key example of a centrally acting antihypertensive.</p>
                    <section class="content-section">
                        <h3>Methyldopa: Aldomin</h3>
                        <div class="content-block">
                            <ul>
                                <li>Trade name: Aldomin.</li>
                                <li>Classification: Antihypertensive, centrally acting antiadrenergic agent.</li>
                                <li>Action: Methyldopa lowers blood pressure by:
                                    <ul>
                                        <li>Stimulating Central Inhibitory Alpha-Adrenergic Receptors: The active metabolite of methyldopa, alpha-methylnorepinephrine, lowers blood pressure (BP) by stimulating central inhibitory alpha-adrenergic receptors in the brain.</li>
                                        <li>Reduced Sympathetic Outflow: This central action reduces sympathetic outflow from the brainstem to the peripheral cardiovascular system, leading to decreased peripheral vascular resistance and reduced blood pressure.</li>
                                    </ul>
                                </li>
                                <li>Uses: Primarily used for:
                                    <ul>
                                        <li>Hypertension: Effective in managing essential hypertension, particularly in pregnant women due to its established safety profile in pregnancy.</li>
                                        <li>Hypertensive crises: Can be used parenterally (IV) to manage hypertensive emergencies, although less common now with newer agents available.</li>
                                    </ul>
                                </li>
                                <li>Contraindications:
                                    <ul>
                                        <li>Hypersensitivity to methyldopa.</li>
                                        <li>Active hepatic diseases: Liver diseases like hepatitis or cirrhosis, as methyldopa can cause hepatotoxicity.</li>
                                        <li>Pheochromocytoma: Tumor of the adrenal gland, as methyldopa can paradoxically increase blood pressure in these patients.</li>
                                    </ul>
                                </li>
                                <li>Side effects: Common side effects include:
                                    <ul>
                                        <li>Central Nervous System: Headache, dizziness, general weakness, marked drowsiness, depression, and sedation, especially at the start of therapy.</li>
                                        <li>Cardiovascular: Bradycardia (slow heart rate), orthostatic hypotension (drop in blood pressure upon standing).</li>
                                        <li>Gastrointestinal: Dry mouth, nausea, vomiting, sore or "black" tongue.</li>
                                        <li>Hepatic: Jaundice and liver disorders, including hepatitis (rare but serious). Regular liver function tests are recommended.</li>
                                        <li>Hematologic: Hemolytic anemia (rare), leukopenia (decreased white blood cells).</li>
                                        <li>Other: Male impotence.</li>
                                    </ul>
                                </li>
                                <li>Dosage:
                                    <ul>
                                        <li>Tablets: Initially 250 mg twice or three times daily (bid or tid).</li>
                                    </ul>
                                </li>
                            </ul>
                        </div>
                    </section>
                    <section class="content-section">
                        <h3>Nursing considerations:-</h3>
                        <div class="content-block">
                            <ul>
                                <li>Activities to avoid: Avoid activities that require mental alertness such as driving, operating machinery, especially when starting therapy or increasing dosage, due to drowsiness and dizziness.</li>
                                <li>Jaundice monitoring: Note any evidence of jaundice, and monitor liver function tests at regular intervals, especially during long-term therapy.</li>
                                <li>Orthostatic Hypotension: Advise patients to rise slowly from sitting or lying positions to minimize orthostatic hypotension and dizziness.</li>
                                <li>Reportable Symptoms: Instruct patients to report any bothersome or persistent side effects, especially signs of liver dysfunction (jaundice, abdominal pain, dark urine) or CNS depression.</li>
                                <li>Urine Discoloration: Explain to patients that urine may rarely turn dark or blue in color, which is a harmless effect of the medication.</li>
                                <li>Medical ID: Advise clients to carry a card detailing their current medication regimen, especially noting methyldopa use, to inform healthcare providers in emergency situations.</li>
                            </ul>
                        </div>
                    </section>
                </div>
            </section>

            <section class="content-section">
                <h2>üìö 5. Agents that act directly on vascular smooth muscles:- Hydralazine hydrochloride</h2>
                <div class="content-block">
                    <p><strong>Hydralazine hydrochloride (Apresoline)</strong> is a direct-acting vasodilator that lowers blood pressure by directly relaxing arteriolar smooth muscle, reducing peripheral resistance.</p>
                    <section class="content-section">
                        <h3>Hydralazine hydrochloride: Apresoline</h3>
                        <div class="content-block">
                            <ul>
                                <li>Trade name: Apresoline.</li>
                                <li>Classification: Antihypertensive, direct-acting vasodilator.</li>
                                <li>Action: Hydralazine directly affects vascular smooth muscles, causing vasodilation, particularly in arterioles. This action leads to:
                                    <ul>
                                        <li>Reduced Peripheral Resistance: Directly dilates arterioles, reducing peripheral vascular resistance, which lowers blood pressure.</li>
                                        <li>Increased Cardiac Output: By reducing afterload (resistance against which the heart pumps), hydralazine can increase cardiac output and improve blood flow to organs like the brain and kidneys.</li>
                                    </ul>
                                </li>
                                <li>Uses: Primarily used for:
                                    <ul>
                                        <li>Hypertension: Often used in combination with other antihypertensive agents, such as diuretics and beta-blockers, to manage moderate to severe hypertension.</li>
                                        <li>Hypertensive emergencies: Can be administered parenterally (IV or IM) in hypertensive emergencies to rapidly lower blood pressure.</li>
                                    </ul>
                                </li>
                                <li>Contraindications:
                                    <ul>
                                        <li>Angina pectoris: May exacerbate angina by causing reflex tachycardia and increased myocardial oxygen demand.</li>
                                        <li>Rheumatic heart disease: Use with caution.</li>
                                        <li>Chronic glomerulonephritis: Use with caution in renal disease.</li>
                                        <li>Systemic lupus erythematosus (SLE): Hydralazine can induce a lupus-like syndrome.</li>
                                    </ul>
                                </li>
                                <li>Side effects: Common side effects include:
                                    <ul>
                                        <li>Cardiovascular: Orthostatic hypotension, reflex tachycardia (increased heart rate in response to lowered blood pressure), palpitations.</li>
                                        <li>Neurological: Headache, dizziness.</li>
                                        <li>Gastrointestinal: Nausea, vomiting, diarrhea.</li>
                                        <li>Other: Constipation, male impotence, nasal congestion.</li>
                                    </ul>
                                </li>
                                <li>Dosage:
                                    <ul>
                                        <li>Tablets: Initially 10 mg four times daily (qid) for 2-4 days, then increased to 25 mg twice daily (bid). Dosage is adjusted based on blood pressure response and tolerance.</li>
                                        <li>I.V. or I.M.: 50 mg, administered IV slowly or IM, repeated as necessary in hypertensive emergencies. May decrease blood pressure within 5 minutes of IV administration.</li>
                                    </ul>
                                </li>
                            </ul>
                        </div>
                    </section>
                </div>
            </section>

            <section class="practice-activity">
                <h2>‚úçÔ∏è Practice Exercise</h2>
                <div class="activity-content">
                    <p><strong>Question:</strong> Compare and contrast Methyldopa and Hydralazine hydrochloride in terms of their mechanisms of action, primary uses in hypertension management, and major side effects. Which conditions might favor the use of Methyldopa over Hydralazine, and vice versa?</p>
                    <details class="solution">
                        <summary>View Solution</summary>
                        <div class="solution-content">
                            <p><strong>Comparison of Methyldopa and Hydralazine Hydrochloride:</strong></p>
                            <ul>
                                <li><strong>Mechanisms of Action:</strong>
                                    <ul>
                                        <li><strong>Methyldopa (Centrally Acting Agent):</strong> Lowers blood pressure by stimulating alpha-adrenergic receptors in the brain, which reduces sympathetic outflow, leading to decreased peripheral vascular resistance and heart rate. It acts centrally within the CNS.</li>
                                        <li><strong>Hydralazine Hydrochloride (Direct Vasodilator):</strong> Lowers blood pressure by directly relaxing vascular smooth muscle, primarily in arterioles, leading to decreased peripheral vascular resistance and afterload. It acts directly on blood vessels.</li>
                                    </ul>
                                </li>
                                <li><strong>Primary Uses in Hypertension Management:</strong>
                                    <ul>
                                        <li><strong>Methyldopa:</strong>
                                            <ul>
                                                <li>Gestational Hypertension: Particularly favored for managing hypertension during pregnancy due to its long-established safety record for both mother and fetus.</li>
                                                <li>Essential Hypertension: Can be used for chronic hypertension, often as a second- or third-line agent due to its side effect profile.</li>
                                                <li>Hypertensive Crises: Can be used intravenously in hypertensive emergencies, although less common now compared to newer agents.</li>
                                            </ul>
                                        </li>
                                        <li><strong>Hydralazine Hydrochloride:</strong>
                                            <ul>
                                                <li>Moderate to Severe Hypertension: Used in combination therapy for managing hypertension, especially when multiple drugs are needed.</li>
                                                <li>Hypertensive Emergencies: Effective for rapid blood pressure reduction in hypertensive emergencies, particularly via parenteral administration.</li>
                                                <li>Heart Failure: In heart failure, particularly in African American patients, combined with isosorbide dinitrate to reduce afterload and improve cardiac output.</li>
                                            </ul>
                                        </li>
                                    </ul>
                                </li>
                                <li><strong>Major Side Effects:</strong>
                                    <ul>
                                        <li><strong>Methyldopa:</strong>
                                            <ul>
                                                <li>CNS Depression: Marked drowsiness, sedation, dizziness, depression, and impaired mental alertness are common, limiting its use in patients needing to be alert.</li>
                                                <li>Orthostatic Hypotension: Significant postural hypotension.</li>
                                                <li>Hepatic Issues: Risk of jaundice and liver disorders.</li>
                                                <li>Other: Dry mouth, nausea, and potential hematologic side effects.</li>
                                            </ul>
                                        </li>
                                        <li><strong>Hydralazine Hydrochloride:</strong>
                                            <ul>
                                                <li>Reflex Tachycardia and Palpitations: Common due to rapid vasodilation, which can increase heart rate and cause palpitations.</li>
                                                <li>Orthostatic Hypotension: Significant postural hypotension.</li>
                                                <li>Headache and Dizziness: Vasodilation-induced headache and dizziness.</li>
                                                <li>Lupus-like Syndrome: Risk of drug-induced lupus erythematosus with long-term use.</li>
                                            </ul>
                                        </li>
                                </li>
                            </ul>
                            <p><strong>Conditions Favoring Use of Each Drug:</strong></p>
                            <ul>
                                <li><strong>Methyldopa Favored When:</strong>
                                    <ul>
                                        <li>Pregnancy-Induced Hypertension: Preferred for hypertension management during pregnancy due to its safety profile.</li>
                                        <li>Patients Needing Central Nervous System Effects: In specific cases where central sympatholytic action is desired, although CNS depression side effects are a significant consideration.</li>
                                    </ul>
                                </li>
                                <li><strong>Hydralazine Hydrochloride Favored When:</strong>
                                    <ul>
                                        <li>Rapid Blood Pressure Reduction Needed: In hypertensive emergencies or situations requiring quick-acting vasodilation, particularly when given IV.</li>
                                        <li>Adjunctive Therapy in Heart Failure: Especially in combination with nitrates for heart failure management to reduce afterload.</li>
                                        <li>Patients Tolerating Reflex Tachycardia: In patients who can tolerate the reflex tachycardia and other vasodilator-related side effects.</li>
                                    </ul>
                                </li>
                            </ul>
                        </div>
                    </details>
                </div>
            </section>
        </main>

        <footer class="module-footer">
            <section class="key-takeaways">
                <h2>üìö Key Takeaways</h2>
                <ul>
                    <li>Centrally acting agents like Methyldopa lower BP by reducing sympathetic outflow from the brainstem; Methyldopa is favored in pregnancy hypertension.</li>
                    <li>Methyldopa side effects include drowsiness, hypotension, and liver issues; nursing care involves monitoring mental alertness and liver function.</li>
                    <li>Hydralazine hydrochloride, a direct vasodilator, acts directly on arterioles to reduce peripheral resistance, used in hypertension and emergencies.</li>
                    <li>Hydralazine side effects include reflex tachycardia and orthostatic hypotension; contraindicated in angina pectoris and certain heart conditions.</li>
                </ul>
            </section>

            <section class="knowledge-check">
                <h2>‚ö° Knowledge Check</h2>
                <div class="quiz-content">
                    <ol>
                        <li>Methyldopa lowers blood pressure by:
                            <br> a) Directly dilating blood vessels <br> b) Stimulating central alpha-adrenergic receptors <br> c) Blocking angiotensin-converting enzyme</li>
                        <li>A key side effect of Hydralazine hydrochloride is:
                            <br> a) Bradycardia <br> b) Reflex tachycardia <br> c) Sedation</li>
                        <li>Methyldopa is often preferred for managing hypertension in:
                            <br> a) Elderly patients <br> b) Pregnant women <br> c) Patients with renal disease</li>
                    </ol>
                </div>
            </section>
        </footer>
    </article>
</body>
</html>

    